Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01183143
Other study ID # IMP 25040
Secondary ID
Status Completed
Phase Phase 3
First received August 16, 2010
Last updated April 5, 2018
Start date May 11, 2004
Est. completion date March 2, 2006

Study information

Verified date April 2018
Source Merck KGaA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This was a prospective, open-label, non-comparative, Phase IIIb trial to assess the convenience, safety and efficacy of the new Gonal-F fbm [recombinant follicle stimulating hormone (r-FSH)] liquid formulation, in common setting for ovulation induction (OI) and also in in-vitro fertilization (IVF).


Recruitment information / eligibility

Status Completed
Enrollment 215
Est. completion date March 2, 2006
Est. primary completion date March 2, 2006
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 43 Years
Eligibility Inclusion Criteria:

- Female subjects aged between 18 and 43 years

- Ambulatory subjects

- Subjects who are willing to get pregnant and are infertile, that justifies ovarian stimulation treatment for mono-/pauci-follicular development (OI or IUI) or multiple follicular development for IVF/Intracytoplasmic Sperm Injection (ICSI) procedures

- Subjects who are able to communicate well with the investigator and to comply with the requirements of the entire study

- Subjects who have given written informed consent, prior to treatment

Exclusion Criteria:

- Subjects with enlarged ovaries or cysts unrelated to polycystic ovaries

- Subjects with extra-uterine pregnancy during the last 3 months

- Subjects with several endometriosis (Grade III & IV)

- Subjects with history of severe ovarian hyperstimulation syndrome

- Subjects with history of thromboembolic event

- Subjects with malformative uterine pathology that could disturb either implantation or pregnancy processes

- Subjects with premature menopause

- Subjects with gynecological bleeding of unknown origin

- Subjects with ovarian, uterine, or mammary cancer

- Subjects with tumors of the hypothalamus or the pituitary glands

- Subjects with history of serious allergy or atopic asthma disease

- Subjects with known allergic reaction against one of the Follicle Stimulating Hormone (FSH) and ingredients,

- Ongoing pregnant, or breast feeding subjects

- Subjects who have participated in a trial during the last 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GONAL-f®
GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.

Locations

Country Name City State
Germany Please Contact the Merck KGaA Communication Center Darmstadt

Sponsors (1)

Lead Sponsor Collaborator
Merck KGaA

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP) Number of subjects who self-administered the IMP were presented in this outcome measure. Up to 1 year
Secondary Global Evaluation of the GONAL-f® Prefilled Pen by the Investigator Investigator evaluated the use of GONAL-f® prefilled pen in subjects as very satisfactory, satisfactory and average satisfaction. Up to 1 year
Secondary Evaluation of the Information Given to the Subjects on the Pen's Utilization Subjects were provided with the information on Pen's utilization via training session and in the form of information brochure. Subjects assessed both the methods using the following responses: satisfactory, satisfactory, unsatisfactory and very unsatisfactory. Up to 1 year
Secondary Duration of Ovarian Stimulation With GONAL-f® Stimulation duration was defined as the duration (in days) for which subjects underwent GONAL-f® treatment. Up to 1 year
Secondary Mean Number of Embryos Transferred End of Stimulation period (up to a maximum 26 days)
Secondary Total and Average Daily Dose of GONAL-f® Up to 26 days
Secondary Pregnancy Rate in Subjects Receiving Stimulation by Ovulation Induction (OI) or Artificial Insemination (IUI) Pregnancy rate was defined as the percentage of subjects with diagnosis of pregnancy, who underwent OI/IUI. Clinical pregnancy: Evidence of pregnancy by clinical or ultrasound parameters at 12 weeks after fertilization. Biochemical pregnancy: Evidence of conception based only on biochemical data in the serum or urine before ultrasound evidence of a gestational sac. Ongoing pregnancy was defined when the pregnancy had completed 20 weeks of gestation. Up to 20 Weeks of Gestation
Secondary Number of Subjects With Live Birth Number of subjects whose stimulation with the IMP resulted in the birth of a baby were reported. End of Gestation period, assessed up to a maximum of 1 year
Secondary Number of Subjects With Local Tolerance at GONAL-f ® Injection Site as Assessed by Investigator Local tolerance at the GONAL-f ® injection site was assessed for the presence of pain, swelling/welt, redness, itch and haematoma. Up to 1 year
Secondary Number of Subjects With at Least 1 Adverse Event An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerged or worsened relative to baseline (i.e. present at the initial study visit) during a clinical study with an investigational product, regardless of causal relationship and even if no investigational product has been administered. Up to 1 year
Secondary Number of Subjects Taking at Least 1 Concomitant Treatment Up to 1 year
See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A